IMM

0.00%

42.0¢

IMMUTEP LIMITED

Market Cap $499.3M Add to my watchlist

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Latest Threads

Tag

Subject

IMM

Overnight Market report

43 44 45

06:21

2.6K

1.0M

06:21

Last post ahjay

2.6K

1.0M

IMM

News: IMM Immutep's Efti Reports Positive Initial Clinical Data

02/05/24

153

02/05/24

Last post

Hot News

153

IMM

Ann: Positive initial data in phase 2 Soft Tissue Sarcoma trial

02/05/24

4.1K

02/05/24

Last post tuts

4.1K

IMM

Ann: Positive preliminary topline results from TACTI-003 Cohort B

30/04/24

22K

30/04/24

Last post ahjay

22K

IMM

Media

11 12 13

30/04/24

741

327K

30/04/24

Last post Bundaone

741

327K

IMM

Ann: Immutep Quarterly Activities Report and Appendix 4C

29/04/24

544

29/04/24

Last post

ASX News

544

IMM

Marc do your job!

27/04/24

17K

27/04/24

Last post Joe007

17K

IMM

TACTI-003 likelihood of success based on data comparison

25/04/24

1.2K

25/04/24

Last post Bylosellhi

1.2K

See All Discussions

Timeline

Positive initial data in phase 2 Soft Tissue Sarcoma trial
02 May 09:29	Share

Immutep Quarterly Activities Report and Appendix 4C
29 Apr 08:18	Share

Positive preliminary topline results from TACTI-003 Cohort B
24 Apr 08:40	Share

CHDR to conduct first-in-human phase 1 trial of IMP761
18 Apr 09:36	Share

Positive Feedback received from Spanish Medicines Agency
17 Apr 09:10	Share

Ceasing to be a substantial holder
11 Apr 18:30	Share

Ceasing to be a substantial holder
08 Mar 16:27	Share

First Clinical Data announced from 90mg Dosing of Efti
05 Mar 12:34	Share

Half Yearly Report and Accounts
28 Feb 09:39	Share

Becoming a substantial holder
26 Feb 16:47	Share

Change in substantial holding
22 Feb 18:14	Share

Immutep Investor Update
21 Feb 16:55	Share

Change in substantial holding
20 Feb 16:46	Share

Becoming a substantial holder
15 Feb 16:45	Share

Ceasing to be a substantial holder
14 Feb 13:05	Share

Appendix 3X - Anne Anderson
14 Feb 10:20	Share

Appointment of Non-Executive Director
14 Feb 09:12	Share

Notification regarding unquoted securities - IMM
31 Jan 19:31	Share

Immutep Quarterly Activities Report and Appendix 4C
30 Jan 08:32	Share

Change in substantial holding
15 Jan 17:03	Share

Immutep Corporate Presentation
08 Jan 08:22	Share

First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial
04 Jan 09:13	Share

Change of Registered Office Address
22 Dec 15:16	Share

PEI provides constructive feedback for ph3 lung cancer trial
21 Dec 08:23	Share

Immutep receives A$2.6 million French R&D Tax Incentive
07 Dec 08:16	Share

Change of Director's Interest Notice - L Boyce
23 Nov 17:24	Share

Change of Director's Interest Notice - R Howard
23 Nov 17:24	Share

Notification regarding unquoted securities - IMM
23 Nov 09:26	Share

Immutep Announces Site Expansion for INSIGHT-003 Trial
22 Nov 12:31	Share

Proposed issue of securities - IMM
22 Nov 10:41	Share

View More

(20min delay)
Last 42.0¢		Change 0.000(0.00%)		Mkt cap ! $499.3M

Open	High	Low	Value	Volume
42.0¢	43.0¢	40.5¢	$1.108M	2.653M

Buyers (Bids)

No.	Vol.	Price($)
1	24000	41.5¢

Sellers (Offers)

Price($)	Vol.	No.
42.0¢	101546	47

View Market Depth

No.	Vol.	Price($)
1	24000	0.415
2	41924	0.410
6	156457	0.405
9	257872	0.400
4	195016	0.395

Price($)	Vol.	No.
0.420	101546	47
0.425	84924	3
0.430	303265	4
0.435	5000	1
0.440	7000	1

Last trade - 16.10pm 02/05/2024 (20 minute delay)


Last 42.0¢		Change 0.000 ( 0.90 %)
Open	High	Low	Volume
43.0¢	43.0¢	41.0¢	749406
Last updated 15.59pm 02/05/2024 ?

IMM (ASX) Chart

IMMUTEP LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Immutep (ASX:IMM) enrols 50pc of patients for TACTI-003 trial

04 Jan 2023 08:19 (AEDT)

Latest Articles

Immutep welcomes constructive feedback from German regulator for phase III lung cancer trial

Immutep (ASX:IMM) has welcomed constructive feedback from a German regulatory authority for its planned TACTI-004 phase III trial of efti for first-line treatment of metastatic NSCLC

Immutep reports new biomarker data from TACTI-002 phase II trial

Immutep (ASX:IMM) has announced new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic NSCLC.

Immutep's Efti and Keytruda combo shows strong survival benefits in metastatic non-small cell lung cancer

Immutep (ASX:IMM) has revealed its drug Efti, in combination with Keytruda, has generated significant survival benefits for those suffering from metastatic non-small cell lung cancer.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News